Abiraterone Acetate for Nonmetastatic Castration-Resistant Prostate Cancer - The Forgotten Dance Partner?

Zachary Klaassen; Christopher J.D. Wallis; Neil E. Fleshner

doi:10.1001/jamaoncol.2018.5191

Abiraterone Acetate for Nonmetastatic Castration-Resistant Prostate Cancer - The Forgotten Dance Partner?

Zachary Klaassen
, Christopher J.D. Wallis
, Neil E. Fleshner

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	144-145
Number of pages	2
Journal	JAMA Oncology
Volume	5
Issue number	2
DOIs	https://doi.org/10.1001/jamaoncol.2018.5191
State	Published - Feb 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1001/jamaoncol.2018.5191

Cite this

@article{b4b2e6614e4241768fd23276b555625a,

title = "Abiraterone Acetate for Nonmetastatic Castration-Resistant Prostate Cancer - The Forgotten Dance Partner?",

author = "Zachary Klaassen and Wallis, \{Christopher J.D.\} and Fleshner, \{Neil E.\}",

note = "Funding Information: reports honoraria, consultancy fees, and research support from Janssen, Astellas, and Bayer, as well as honoraria and consultancy fees from Abbvie. No other conflicts are reported.",

year = "2019",

month = feb,

doi = "10.1001/jamaoncol.2018.5191",

language = "English (US)",

volume = "5",

pages = "144--145",

journal = "JAMA Oncology",

issn = "2374-2437",